Celgene Co. (NASDAQ:CELG) Stock Holdings Lowered by HGK Asset Management Inc.

HGK Asset Management Inc. lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 6.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,403 shares of the biopharmaceutical company’s stock after selling 158 shares during the period. HGK Asset Management Inc.’s holdings in Celgene were worth $222,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Capital Management Corp VA bought a new position in shares of Celgene during the first quarter worth about $10,955,000. Oregon Public Employees Retirement Fund grew its position in Celgene by 4.6% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 273,716 shares of the biopharmaceutical company’s stock valued at $25,302,000 after buying an additional 12,071 shares in the last quarter. Canyon Capital Advisors LLC bought a new position in Celgene in the 1st quarter valued at about $119,226,000. Tibra Equities Europe Ltd bought a new position in Celgene in the 1st quarter valued at about $6,396,000. Finally, Gilman Hill Asset Management LLC grew its position in Celgene by 18.6% in the 2nd quarter. Gilman Hill Asset Management LLC now owns 7,416 shares of the biopharmaceutical company’s stock valued at $686,000 after buying an additional 1,165 shares in the last quarter. Institutional investors and hedge funds own 74.84% of the company’s stock.

NASDAQ CELG traded down $0.10 on Tuesday, reaching $92.89. The company’s stock had a trading volume of 89,520 shares, compared to its average volume of 3,638,123. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $98.97. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $65.42 billion, a PE ratio of 12.20, a PEG ratio of 0.44 and a beta of 1.45. The business has a 50 day moving average price of $93.67.

A number of equities analysts recently issued reports on the stock. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Zacks Investment Research lowered shares of Phoenix New Media from a “hold” rating to a “sell” rating in a research report on Tuesday, July 23rd. Atlantic Securities lowered shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.34 target price for the company. in a research report on Monday, April 1st. Mizuho set a $148.00 target price on shares of Jazz Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, July 3rd. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $94.81.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.